FDAsafety guidance66% confidence
FDA AP — PAVBLU (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Amgen; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761298. Sponsor: AMGEN INC. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: AFLIBERCEPT-AYYH.
Supporting Context
- Therapeutic area
- Oncology · Biologic Therapy
- Sub-indication
- General
Related signal: FDA Accepts Application for PAVBLU (Aflibercept-AYYH) from Amgen